Octaarginine (R8) in DSPE-PEG2000-R8 (post-inserted)
Sequence: Ac-Cys-βAla-(Arg)8-H
| Experiment Id | EXP001695 |
|---|---|
| Paper | In Vitro Investigations of the Efficacy of Cyclodextrin-siRNA Complexes Modified with Lipid-PEG-Octa |
| Peptide | Octaarginine (R8) in DSPE-PEG2000-R8 (post-inserted) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | MR20 complexes with 20 mol% DSPE-PEG2000-R8; dose as formulated nanoparticles |
| Rna Concentration | 40 µg FAM-siRNA injected per mouse (formulated or free) |
| Mixing Ratio | CD:siRNA MR=20; 20 mol% DSPE-PEG2000-R8 |
| Formulation Format | R8-PEG-DSPE post-inserted CD/siRNA nanoparticles (concentrated by ultrafiltration for PK study) |
| Formulation Components | SC12CDclickpropylamine + FAM-siRNA + DSPE-PEG2000-R8 |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Male Balb/c mice (8–10 weeks) |
| Administration Route | Intravenous (tail vein) |
| Output Type | pharmacokinetics (plasma) |
| Output Value | Formulated siRNA half-life 15.7±4.4 min vs free siRNA 2.3±0.9 min; ~3× higher plasma levels at 10 min vs free siRNA. |
| Output Units | |
| Output Notes | Plasma FAM-siRNA quantified by fluorescence after extraction; effect described as modest prolongation. |
| Toxicity Notes | |
| Curation Notes |